Infant Bacterial Therapeutics AB (CHIX:IBTBS) Current Deferred Revenue: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IBTBS Infant Bacterial Therapeutics AB CHIX:IBTBS
27 GF Score
Price kr109.00
! 1 Warning Sign
View Full Analysis

What is Infant Bacterial Therapeutics AB Current Deferred Revenue?

Infant Bacterial Therapeutics AB CHIX:IBTBS 27 Current Deferred Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus rates CHIX:IBTBS with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Infant Bacterial Therapeutics AB's current deferred revenue for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Infant Bacterial Therapeutics AB Current Deferred Revenue Related Terms

Infant Bacterial Therapeutics AB Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Infant Bacterial Therapeutics AB's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB Current Deferred Revenue Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Infant Bacterial Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:IBTBS
27GF Score
Infant Bacterial Therapeutics AB CHIX:IBTBS
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of kr0.00 Mil mean?
Infant Bacterial Therapeutics AB (CHIX:IBTBS) has a Current Deferred Revenue of kr0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Infant Bacterial Therapeutics AB and its competitors.
Is Infant Bacterial Therapeutics AB's Current Deferred Revenue too high?
Infant Bacterial Therapeutics AB's current Current Deferred Revenue is kr0.00 Mil. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's Current Deferred Revenue compare to VRTX and REGN?
Infant Bacterial Therapeutics AB's Current Deferred Revenue of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Infant Bacterial Therapeutics AB and its competitors. Infant Bacterial Therapeutics AB's current Current Deferred Revenue is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (CHIX:IBTBS) has a current Current Deferred Revenue of kr0.00 Mil. The current Current Deferred Revenue is kr0.00 Mil. Infant Bacterial Therapeutics AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (CHIX:IBTBS), the current Current Deferred Revenue is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infant Bacterial Therapeutics AB Business Description

Other Exchanges IBT B:Sweden9IB:Germany
Address Katarina Bangata 70, Stockholm, SWE, 116 42
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
27GF Score

Get the complete analysis for CHIX:IBTBS

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr109.00
Price